Boston-based Aktis Oncology is making significant strides in the biopharmaceutical industry, standing out for its innovative efforts in developing radiopharmaceutical medicines aimed at treating cancer. The company recently secured a substantial $175 million in a Series B funding round, designed to
BioAge Labs has recently garnered significant attention with its successful initial public offering (IPO), raising a formidable $198 million. Demonstrating the company's strategic pivot towards obesity drug research, this financial feat is particularly notable given the challenging environment
Mpox has made a concerning comeback, compelling immediate and collaborative action. With an increased threat from the Clade Ib strain, the situation demands an effective response framework modeled after successful strategies used in the COVID-19 pandemic. This involves substantial input from both
In a significant move for maternal and neonatal healthcare, Danish biotech company MinervaX has teamed up with German CDMO Wacker Biotech to develop a groundbreaking prophylactic vaccine for Group B Streptococcus (GBS) infections. This partnership marks a pivotal step in addressing a critical unmet
The world of cancer treatment is ever-evolving, and recent developments have brought a glimmer of hope for those battling non-small cell lung cancer (NSCLC). iTeos Therapeutics has unveiled promising results from a mid-stage clinical trial examining the efficacy of combining their drug,
Sleep disorders are a growing public health concern, impacting millions of individuals worldwide. Addressing these disorders effectively has long been a challenge for pharmaceutical companies. Enter Centessa Pharmaceuticals, a London-based biotechnology company that has made headlines with its
